Panagora Asset Management’s Supernus Pharmaceuticals SUPN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-18,185
| Closed | -$659K | – | 1466 |
|
|
2023
Q1 | $659K | Buy |
+18,185
| New | +$699K | ﹤0.01% | 1017 |
|
|
2021
Q3 | – | Sell |
-142
| Closed | -$4K | – | 2326 |
|
|
2021
Q2 | $4K | Sell |
142
-4,321
| -97% | -$132K | ﹤0.01% | 2540 |
|
|
2021
Q1 | $117K | Sell |
4,463
-29,071
| -87% | -$813K | ﹤0.01% | 1929 |
|
|
2020
Q4 | $844K | Sell |
33,534
-10,635
| -24% | -$229K | 0.01% | 1040 |
|
|
2020
Q3 | $920K | Sell |
44,169
-152,183
| -78% | -$3.45M | 0.01% | 931 |
|
|
2020
Q2 | $4.66M | Buy |
196,352
+62,310
| +46% | +$1.38M | 0.03% | 423 |
|
|
2020
Q1 | $2.41M | Sell |
134,042
-227,209
| -63% | -$4.77M | 0.02% | 539 |
|
|
2019
Q4 | $8.57M | Buy |
361,251
+18,252
| +5% | +$443K | 0.04% | 359 |
|
|
2019
Q3 | $9.43M | Sell |
342,999
-23,004
| -6% | -$682K | 0.04% | 341 |
|
|
2019
Q2 | $12.1M | Sell |
366,003
-7,480
| -2% | -$256K | 0.05% | 304 |
|
|
2019
Q1 | $13.1M | Buy |
373,483
+126,743
| +51% | +$4.72M | 0.06% | 298 |
|
|
2018
Q4 | $8.2M | Buy |
246,740
+3,557
| +1% | +$153K | 0.04% | 353 |
|
|
2018
Q3 | $12.2M | Sell |
243,183
-1,538
| -0.6% | -$76K | 0.05% | 322 |
|
|
2018
Q2 | $14.6M | Sell |
244,721
-11,319
| -4% | -$586K | 0.06% | 275 |
|
|
2018
Q1 | $11.7M | Sell |
256,040
-6,125
| -2% | -$256K | 0.05% | 328 |
|
|
2017
Q4 | $10.4M | Sell |
262,165
-4,490
| -2% | -$177K | 0.04% | 381 |
|
|
2017
Q3 | $10.7M | Sell |
266,655
-141,638
| -35% | -$6.13M | 0.04% | 389 |
|
|
2017
Q2 | $17.6M | Buy |
408,293
+100,653
| +33% | +$3.58M | 0.07% | 273 |
|
|
2017
Q1 | $9.63M | Sell |
307,640
-586
| -0.2% | -$15.7K | 0.04% | 428 |
|
|
2016
Q4 | $7.78M | Buy |
308,226
+1,359
| +0.4% | +$30.4K | 0.04% | 433 |
|
|
2016
Q3 | $7.59M | Sell |
306,867
-23,810
| -7% | -$539K | 0.04% | 431 |
|
|
2016
Q2 | $6.74M | Buy |
330,677
+27,805
| +9% | +$493K | 0.03% | 463 |
|
|
2016
Q1 | $4.62M | Buy |
302,872
+72,517
| +31% | +$946K | 0.02% | 601 |
|
|
2015
Q4 | $3.1M | Buy |
230,355
+33,294
| +17% | +$515K | 0.02% | 677 |
|
|
2015
Q3 | $2.77M | Sell |
197,061
-16,115
| -8% | -$300K | 0.01% | 669 |
|
|
2015
Q2 | $3.62M | Sell |
213,176
-20,308
| -9% | -$289K | 0.02% | 609 |
|
|
2015
Q1 | $2.82M | Buy |
233,484
+95,499
| +69% | +$902K | 0.01% | 669 |
|
|
2014
Q4 | $1.15M | Sell |
137,985
-1,026
| -0.7% | -$8.62K | 0.01% | 988 |
|
|
2014
Q3 | $1.21M | Sell |
139,011
-7,291
| -5% | -$65.9K | 0.01% | 956 |
|
|
2014
Q2 | $1.6M | Buy |
146,302
+7,391
| +5% | +$65.8K | 0.01% | 897 |
|
|
2014
Q1 | $1.24M | Sell |
138,911
-1,145
| -0.8% | -$10.5K | 0.01% | 1084 |
|
|
2013
Q4 | $1.06M | Buy |
140,056
+1,700
| +1% | +$11.9K | ﹤0.01% | 1154 |
|
|
2013
Q3 | $1.01M | Buy |
138,356
+106,938
| +340% | +$718K | 0.01% | 1110 |
|
|
2013
Q2 | $202K | Buy |
+31,418
| New | +$185K | ﹤0.01% | 1633 |
|
Other funds holding SUPN
AC
SIMG
PCH
Panagora Asset Management's SUPN Position: Q2 2023 in Review
Panagora Asset Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2023, closing a stake of 18,185 shares — an estimated $659K sold.
Panagora Asset Management first reported a position in SUPN in Q2 2013 and held it in 34 quarters. The position peaked at $17.6M in Q2 2017. 249 funds tracked by Wall St. Rank hold SUPN as of Q2 2023.
- Panagora Asset Management reported no remaining Supernus Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
- Panagora Asset Management sold 18,185 Supernus Pharmaceuticals shares in Q2 2023, an estimated $659K.
- Panagora Asset Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 34 quarters.
- Panagora Asset Management's Supernus Pharmaceuticals position peaked at $17.6M in Q2 2017.
- 249 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2023.
Based on Panagora Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.